[August 01, 2017] |
|
Pfizer Reports Second-Quarter 2017 Results
Pfizer Inc. (NYSE:PFE) reported financial results for second-quarter
2017, increased the midpoint of its 2017 financial guidance range for
Adjusted diluted EPS(2) and reaffirmed its 2017 financial
guidance range for Revenues.
Results for the second quarter and first six months of 2017 and 2016(3)
are summarized below.
OVERALL RESULTS
|
|
($ in millions, except
per share amounts)
|
|
Second-Quarter
|
|
|
Six Months
|
|
|
2017
|
|
2016
|
|
Change
|
|
|
2017
|
|
2016
|
|
Change
|
Revenues
|
|
$
|
|
12,896
|
|
$
|
|
13,147
|
|
(2
|
%)
|
|
|
$
|
|
25,675
|
|
$
|
|
26,152
|
|
(2
|
%)
|
Reported Net Income(1)
|
|
|
|
3,073
|
|
|
|
2,047
|
|
50
|
%
|
|
|
|
|
6,194
|
|
|
|
5,085
|
|
22
|
%
|
Reported Diluted EPS(1)
|
|
|
|
0.51
|
|
|
|
0.33
|
|
53
|
%
|
|
|
|
|
1.02
|
|
|
|
0.82
|
|
24
|
%
|
Adjusted Income(2)
|
|
|
|
4,063
|
|
|
|
3,929
|
|
3
|
%
|
|
|
|
|
8,255
|
|
|
|
8,105
|
|
2
|
%
|
Adjusted Diluted EPS(2)
|
|
|
|
0.67
|
|
|
|
0.64
|
|
5
|
%
|
|
|
|
|
1.36
|
|
|
|
1.31
|
|
4
|
%
|
|
|
REVENUES
|
|
($ in millions)
|
Second-Quarter
|
|
|
Six Months
|
|
|
2017
|
|
|
2016
|
|
% Change
|
|
|
|
2017
|
|
|
2016
|
|
% Change
|
|
|
|
Total
|
|
Oper.
|
|
|
|
|
Total
|
|
Oper.
|
Innovative Health
|
$
|
7,671
|
|
$
|
7,105
|
|
8
|
%
|
|
9
|
%
|
|
|
$
|
15,086
|
|
$
|
14,139
|
|
7
|
%
|
|
8
|
%
|
Essential Health
|
|
5,226
|
|
|
6,042
|
|
(14
|
%)
|
|
(12
|
%)
|
|
|
|
10,590
|
|
|
12,013
|
|
(12
|
%)
|
|
(10
|
%)
|
Total Company
|
$
|
12,896
|
|
$
|
13,147
|
|
(2
|
%)
|
|
-
|
|
|
|
$
|
25,675
|
|
$
|
26,152
|
|
(2
|
%)
|
|
(1
|
%)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Excluding HIS revenues from all periods:
|
|
|
|
|
|
|
|
|
|
Total Company
|
$
|
12,896
|
|
$
|
12,852
|
|
-
|
|
|
2
|
%
|
|
|
$
|
25,578
|
|
$
|
25,553
|
|
-
|
|
|
1
|
%
|
Essential Health
|
|
5,226
|
|
|
5,746
|
|
(9
|
%)
|
|
(7
|
%)
|
|
|
|
10,493
|
|
|
11,414
|
|
(8
|
%)
|
|
(6
|
%)
|
|
Acquisitions and divestitures completed in 2016 and the first six months
of 2017 impacted financial results in the periods presented.(4)
Some amounts in this press release may not add due to rounding. All
percentages have been calculated using unrounded amounts. References to
operational variances pertain to period-over-period growth rates that
exclude the impact of foreign exchange.(5)
2017 FINANCIAL GUIDANCE(6)
The midpoint of the guidance range for Adjusted diluted EPS(2)
was increased by $0.02 to an updated range of $2.54 to $2.60, reflecting
a $300 million increase to the guidance for Adjusted Other
(Income)/Deductions(2) due to lower-than-forecasted net
interest expense as well as higher-than-forecasted royalty income from
certain products and dividend income from ViiV Healthcare Ltd. (ViiV).
Additionally, the updated financial guidance absorbs $75 million
of Adjusted research and development expenses(2) that
were recorded in second-quarter 2017 resulting from our May 2017
agreement with Sangamo Therapeutics, Inc. (Sangamo) to develop and
commercialize gene therapy programs for Hemophilia A.
Pfizer's updated 2017 financial guidance is presented below:
|
Revenues
|
|
|
$52.0 to $54.0 billion
|
Adjusted Cost of Sales(2) as a Percentage of Revenues
|
|
|
20.0% to 21.0%
|
Adjusted SI&A Expenses(2)
|
|
|
$13.7 to $14.7 billion
|
Adjusted R&D Expenses(2)
|
|
|
$7.5 to $8.0 billion
|
Adjusted Other (Income)/Deductions(2)
|
|
|
Approximately $200 million of income
|
|
|
(previously approximately $100 million of deductions)
|
Effective Tax Rate on Adjusted Income(2)
|
|
|
Approximately 23.0%
|
Adjusted Diluted EPS(2)
|
|
|
$2.54 to $2.60
|
|
|
(previously $2.50 to $2.60)
|
|
CAPITAL ALLOCATION
-
During the first six months of 2017, Pfizer returned $8.9 billion
directly to shareholders, through a combination of:
-
$3.9 billion of dividend payments, composed of $0.32 per share of
common stock in each of the first and second quarters of 2017; and
-
a $5.0 billion accelerated share repurchase agreement executed in
February 2017 and completed in May 2017, which resulted in a
reduction of approximately 150 million shares of Pfizer's
outstanding common stock.
-
As of August 1, 2017, Pfizer's remaining share repurchase
authorization was approximately $6.4 billion.
EXECUTIVE COMMENTARY
Ian Read, Chairman and Chief Executive Officer, stated, "I am pleased
with our second-quarter 2017 results and our year-to-date performance is
in line with our expectations. Revenues for the quarter increased 2%
operationally, excluding the unfavorable impacts of the HIS divestiture
and foreign exchange. Innovative Health revenues grew 9% operationally,
driven by the performance of our key growth drivers, notably Ibrance,
Eliquis, Xeljanz and Xtandi. While Essential Health revenues for the
quarter declined 12% operationally primarily due to continued headwinds
from products that recently lost marketing exclusivity, we had solid
operational growth in emerging markets and in biosimilars. I believe the
continued strength from both businesses' key growth drivers positions
the Company for long-term success.
"We have a strong pipeline with a steady flow of scientific innovation
coming from all of our key therapeutic areas. Over the next five years,
we project the potential for approximately 25 to 30 approvals of which
up to 15 have the potential to be blockbusters, and we believe half of
these potential blockbusters could receive approval by 2020. Our
strategy remains focused on maximizing in-market opportunities while
continuing to advance the pipeline and managing our cost structure to
deliver attractive financial performance over time," Mr. Read concluded.
Frank D'Amelio, Executive Vice President, Business Operations and Chief
Financial Officer, stated, "Today we raised the midpoint of our Adjusted
diluted EPS(2) guidance range by $0.02 to a range of $2.54 to
$2.60 to reflect a $300 million increase to the guidance for Adjusted
Other (Income)/Deductions(2) as well as our strong
operational performance to date and confidence in the business going
forward. The midpoint of our new guidance range for Adjusted diluted EPS(2)
represents 7% growth compared with last year."
QUARTERLY FINANCIAL HIGHLIGHTS (Second-Quarter 2017 vs.
Second-Quarter 2016)
Second-quarter 2017 revenues totaled $12.9 billion, a decline of $251
million, or 2% compared to the prior-year quarter, reflecting a slight
operational decline of $48 million and the unfavorable impact of foreign
exchange of $202 million, or 2%.
Excluding the revenues for HIS in both periods and the unfavorable
impact of foreign exchange, second-quarter 2017 revenues increased by
$248 million, or 2%. Second-quarter 2017 revenues excluding the net
impact of acquisitions and divestitures completed in 2016 and the first
six months of 2017 were flat operationally compared to second-quarter
2016.
Innovative Health Highlights
-
IH revenues increased 9% operationally in second-quarter 2017, driven
by continued growth from key brands including Ibrance and Eliquis
globally, the addition of Xtandi revenues in the U.S. resulting from
the September 2016 acquisition of Medivation, as well as Xeljanz and
Lyrica, both primarily in the U.S. Global Ibrance revenues increased
67% operationally while global operational revenue growth for Eliquis
and Xeljanz was 52% and 56%, respectively.
-
Second-quarter 2017 operational growth was negatively impacted by
lower revenues for Enbrel in most developed Europe markets, primarily
due to continued biosimilar competition.
-
Global Prevnar 13/Prevenar 13 revenues declined 7% operationally in
second-quarter 2017. In the U.S., Prevnar 13 revenues decreased 16%,
primarily due to the unfavorable timing of government purchases for
the pediatric indication and the continued decline in revenues for the
Adult indication due to a smaller remaining "catch up" opportunity
compared to the prior-year quarter. Prevenar 13 revenues in
international markets increased 8% operationally, primarily due to the
favorable timing of government purchases in certain emerging markets
for the pediatric indication.
Essential Health Highlights
-
Second-quarter 2017 EH revenues declined 12% operationally, of which
5% operationally was due to the February 2017 divestiture of HIS.
Second-quarter 2017 EH revenues were also negatively impacted by a 27%
operational decline from Peri-LOE Products, including declines in
Pristiq in the U.S., which lost marketing exclusivity in the U.S. in
March 2017, as well as Vfend and Lyrica, both in developed Europe, and
a 3% operational decline from Legacy Established Products (LEP). These
declines were partially offset by 60% operational growth from
Biosimilars, primarily driven by Inflectra in certain developed Europe
markets and in the U.S.
-
Developed markets revenues declined 18% operationally, of which 5%
operationally was due to the February 2017 divestiture of HIS. EH
developed markets revenues were also negatively impacted by a 40%
operational decline from Peri-LOE Products and a 9% operational
decline from the LEP portfolio, partially offset by 63% operational
growth from Biosimilars.
-
Revenues in emerging markets grew 5% operationally, primarily driven
by 7% operational growth from the LEP portfolio and 10% operational
growth from the SIP portfolio. Excluding HIS from both periods, EH
revenues in emerging markets grew 6% operationally.
GAAP Reported(1) Income Statement Highlights
SELECTED TOTAL COMPANY REPORTED COSTS AND EXPENSES(1)
|
|
($ in millions)
(Favorable)/Unfavorable
|
|
Second-Quarter
|
|
|
Six Months
|
|
|
|
2017
|
|
|
2016
|
|
|
% Change
|
|
|
|
2017
|
|
|
2016
|
|
|
% Change
|
|
|
|
|
|
Total
|
|
Oper.
|
|
|
|
|
|
Total
|
|
Oper.
|
Cost of Sales(1)
|
|
$
|
2,663
|
|
$
|
3,174
|
|
|
(16
|
%)
|
|
(10
|
%)
|
|
|
$
|
5,134
|
|
$
|
6,026
|
|
|
(15
|
%)
|
|
(11
|
%)
|
Percent of Revenues
|
|
|
20.7
|
%
|
|
24.1
|
%
|
|
N/A
|
|
N/A
|
|
|
|
20.0
|
%
|
|
23.0
|
%
|
|
N/A
|
|
N/A
|
SI&A Expenses(1)
|
|
|
3,425
|
|
|
3,471
|
|
|
(1
|
%)
|
|
-
|
|
|
|
|
6,733
|
|
|
6,856
|
|
|
(2
|
%)
|
|
(1
|
%)
|
R&D Expenses(1)
|
|
|
1,780
|
|
|
1,748
|
|
|
2
|
%
|
|
3
|
%
|
|
|
|
3,487
|
|
|
3,478
|
|
|
-
|
|
|
1
|
%
|
Total
|
|
$
|
7,868
|
|
$
|
8,392
|
|
|
(6
|
%)
|
|
(3
|
%)
|
|
|
$
|
15,354
|
|
$
|
16,359
|
|
|
(6
|
%)
|
|
(4
|
%)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (Income)/Deductions--net(1)
|
|
|
($66
|
)
|
$
|
1,068
|
|
|
*
|
|
*
|
|
|
|
($68
|
)
|
$
|
1,398
|
|
|
*
|
|
*
|
Effective Tax Rate on Reported Income(1)
|
|
|
19.4
|
%
|
|
14.4
|
%
|
|
|
|
|
|
|
|
20.1
|
%
|
|
14.4
|
%
|
|
|
|
|
|
* Indicates calculation not meaningful.
|
|
Adjusted(2) Income Statement Highlights
SELECTED TOTAL COMPANY ADJUSTED COSTS AND EXPENSES(2)
|
|
($ in millions)
(Favorable)/Unfavorable
|
|
Second-Quarter
|
|
|
Six Months
|
|
|
|
2017
|
|
|
2016
|
|
|
% Change
|
|
|
|
2017
|
|
|
2016
|
|
|
% Change
|
|
|
|
|
|
Total
|
|
Oper.
|
|
|
|
|
|
Total
|
|
Oper.
|
Adjusted Cost of Sales(2)
|
|
$
|
2,595
|
|
$
|
3,062
|
|
|
(15
|
%)
|
|
(9
|
%)
|
|
|
$
|
5,029
|
|
$
|
5,627
|
|
|
(11
|
%)
|
|
(7
|
%)
|
Percent of Revenues
|
|
|
20.1
|
%
|
|
23.3
|
%
|
|
N/A
|
|
N/A
|
|
|
|
19.6
|
%
|
|
21.5
|
%
|
|
N/A
|
|
N/A
|
Adjusted SI&A Expenses(2)
|
|
|
3,385
|
|
|
3,443
|
|
|
(2
|
%)
|
|
-
|
|
|
|
|
6,673
|
|
|
6,811
|
|
|
(2
|
%)
|
|
(1
|
%)
|
Adjusted R&D Expenses(2)
|
|
|
1,771
|
|
|
1,740
|
|
|
2
|
%
|
|
2
|
%
|
|
|
|
3,476
|
|
|
3,463
|
|
|
-
|
|
|
1
|
%
|
Total
|
|
$
|
7,750
|
|
$
|
8,246
|
|
|
(6
|
%)
|
|
(3
|
%)
|
|
|
$
|
15,178
|
|
$
|
15,901
|
|
|
(5
|
%)
|
|
(3
|
%)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted Other (Income)/Deductions--net(2)
|
|
|
($170
|
)
|
|
($230
|
)
|
|
(26
|
%)
|
|
(43
|
%)
|
|
|
|
($258
|
)
|
|
($380
|
)
|
|
(32
|
%)
|
|
(51
|
%)
|
Effective Tax Rate on Adjusted Income(2)
|
|
|
22.9
|
%
|
|
22.7
|
%
|
|
|
|
|
|
|
|
22.6
|
%
|
|
23.1
|
%
|
|
|
|
|
|
The diluted weighted-average shares outstanding used to calculate
Reported(1) and Adjusted(2) diluted EPS declined
by 112 million shares compared to the prior-year quarter due to Pfizer's
share repurchase program, reflecting the impact of a $5 billion
accelerated share repurchase agreement executed in March 2016 and
completed in June 2016 and another $5 billion accelerated share
repurchase agreement executed in February 2017 and completed in May 2017.
A full reconciliation of Reported(1) to Adjusted(2)
financial measures and associated footnotes can be found starting on
page 18 of the press release located at the hyperlink below.
RECENT NOTABLE DEVELOPMENTS (Since May 2, 2017)
Product Developments
-
Bavencio (avelumab)
-
In July 2017, Merck KGaA, Darmstadt, Germany (Merck KGaA) and
Pfizer announced that the Committee for Medicinal Products for
Human Use (CHMP) of the European Medicines Agency (EMA)
recommended the approval of avelumab as a monotherapy for the
treatment of adult patients with metastatic Merkel cell carcinoma
(mMCC), a rare and aggressive skin cancer. The European Commission
(EC) will now review the CHMP's recommendation, with a decision
expected in the third quarter of 2017. Bavencio was previously
granted accelerated approval from the U.S. Food and Drug
Administration (FDA) for the treatment of adults and pediatric
patients 12 years and older with mMCC based on tumor response and
duration of response. Continued FDA approval for this indication
may be contingent upon verification and description of clinical
benefit in confirmatory trials.
-
In May 2017, EMD Serono Inc., the biopharmaceutical business of
Merck KGaA in the U.S. and Canada, and Pfizer announced that the
FDA approved Bavencio for the treatment of patients with locally
advanced or metastatic urothelial carcinoma who have disease
progression during or following platinum-containing chemotherapy,
or who have disease progression within 12 months of neoadjuvant or
adjuvant treatment with platinum-containing chemotherapy. This
indication was approved under accelerated approval based on tumor
response and duration of response. Continued approval for this
indication may be contingent upon verification and description of
clinical benefit in confirmatory trials.
-
Besponsa (inotuzumab ozogamicin) -- In June 2017, Pfizer
announced that the EC approved Besponsa as monotherapy for the
treatment of adults with relapsed or refractory CD22-positive B-cell
precursor acute lymphoblastic leukemia (ALL). This indication includes
treatment of adults with Philadelphia chromosome positive (Ph+) as
well as Philadelphia chromosome negative (Ph-) relapsed or refractory
B-cell precursor ALL. Adults with Ph+ relapsed or refractory
CD22-positive B-cell precursor ALL should have failed treatment with
at least one tyrosine kinase inhibitor. With this approval, Besponsa
became the first and only antibody drug conjugate (ADC) available for
patients with this type of leukemia in the European Union (EU). In the
U.S., Besponsa received Breakthrough Therapy designation from the FDA
in October 2015 for ALL. A Biologics License Application (BLA) for
Besponsa for the treatment of adult patients with relapsed or
refractory B-cell precursor ALL was accepted for filing and granted
Priority Review by the FDA in February 2017. The Prescription Drug
User Fee Act (PDUFA) goal date for a decision by the FDA is in August
2017.
-
Mylotarg (gemtuzumab ozogamicin) -- In July 2017, Pfizer
announced that the FDA's Oncologic Drug Advisory Committee (ODAC)
voted 6-1 that Mylotarg in combination with chemotherapy has a
favorable risk-benefit profile for patients with newly-diagnosed
CD33-positive acute myeloid leukemia (AML). The role of the ODAC is to
provide recommendations to the FDA. The PDUFA goal date for a decision
by the FDA is in September 2017.
-
Retacrit (proposed epoetin alpha biosimilar) -- In June 2017,
Pfizer announced that it received a Complete Response Letter (CRL)
from the FDA regarding the Company's BLA for its proposed epoetin alfa
biosimilar. This CRL relates to matters noted in a Warning Letter
issued in February 2017 following a routine FDA inspection of Pfizer's
manufacturing facility in McPherson, Kansas in 2016. This facility was
listed as the potential manufacturing site in the BLA for the proposed
epoetin alfa biosimilar. The issues noted in the Warning Letter do not
relate specifically to the manufacture of epoetin alfa. No additional
clinical data was requested in the CRL. An ODAC voted in May 2017 to
recommend this proposed biosimilar for approval.
-
Sutent (sunitinib malate) -- In May 2017, Pfizer announced that
a supplemental New Drug Application (sNDA) for Sutent was accepted for
filing by the FDA. If approved, the sNDA would expand the approved use
of Sutent to include use as an adjuvant treatment in adult patients at
high risk of recurrent renal cell carcinoma (RCC) following
nephrectomy (surgical removal of the cancer-containing kidney). In
addition, the EMA has validated for review a Type II Variation
application for Sutent in the same patient population. The PDUFA goal
date for a decision by the FDA is in January 2018.
-
Trumenba (Meningococcal Serogroup B Bivalent Recombinant
Lipoprotein vaccine) -- In May 2017, Pfizer announced that the EC
approved Trumenba for the prevention of invasive meningococcal disease
caused by Neisseria meningitidis serogroup B in individuals 10
years of age and older.
-
Vyndaqel (tafamidis) -- In June 2017, Pfizer announced that the
FDA granted Fast Track designation to tafamidis, the Company's
investigational treatment for transthyretin cardiomyopathy (TTR-CM).
This rare disease is associated with progressive heart failure and is
universally fatal. Currently in Phase 3 clinical development for
TTR-CM, tafamidis is being evaluated for its potential to reduce
mortality and cardiovascular-related hospitalizations. The FDA's Fast
Track approach is a process designed to facilitate the development and
expedite the review of new drugs and vaccines intended to treat or
prevent serious conditions and address an unmet medical need. Vyndaqel
was first approved in 2011 in the EU for the treatment of
transthyretin familial amyloid polyneuropathy (TTR-FAP) in adult
patients with early-stage symptomatic polyneuropathy to delay
peripheral neurologic impairment and is currently approved for TTR-FAP
in 40 countries. Pfizer received a CRL from the FDA on its application
to approve tafamidis for TTR-FAP in 2012; tafamidis is not approved in
the U.S.
-
Xeljanz (tofacitinib citrate)
-
In July 2017, Pfizer announced that the FDA accepted for review a
sNDA for Xeljanz for the treatment of adult patients with
moderately to severely active ulcerative colitis. The PDUFA goal
date for a decision by the FDA is in March 2018.
-
In May 2017, Pfizer announced that the FDA accepted for review a
sNDA for Xeljanz 5 mg twice daily for the treatment of adult
patients with active psoriatic arthritis (PsA). A separate sNDA
was also accepted for Xeljanz XR extended release 11 mg once daily
use in PsA. The PDUFA goal date for a decision by the FDA is in
December 2017. The FDA's Arthritis Advisory Committee is scheduled
to meet on August 3, 2017 to discuss the efficacy and safety data
as well as benefit-risk considerations for these sNDAs.
-
Xtandi (enzalutamide) -- In June 2017, Astellas Pharma Inc.
(Astellas) and Pfizer announced the amendment of the protocol for the
registrational PROSPER trial, a multi-national, randomized,
double-blind, placebo-controlled study evaluating the efficacy and
safety of Xtandi in patients with non-metastatic castration-resistant
prostate cancer (CRPC). The primary endpoint of the PROSPER trial
remains the same: metastasis-free survival. The main purpose of the
amendment is to revise the plan for the analyses of the primary and
several secondary endpoints, which allows for a reduction in the
target sample size to approximately 1,440 from 1,560 patients. The
companies now anticipate PROSPER top-line results will be disclosed
later this year. Previously the expected primary completion date for
PROSPER was June 2019. Xtandi is currently approved by the FDA for the
treatment of patients with metastatic CRPC.
Pipeline Developments
A comprehensive update of Pfizer's development pipeline was published
today and is now available at www.pfizer.com/science/drug-product-pipeline.
It includes an overview of Pfizer's research and a list of compounds in
development with targeted indication and phase of development, as well
as mechanism of action for some candidates in Phase 1 and all candidates
from Phase 2 through registration.
-
Ertugliflozin (PF-04971729) -- In June 2017, Merck, known as
MSD outside the U.S. and Canada, in partnership with Pfizer, announced
that two Phase 3 studies (VERTIS MET and VERTIS SITA) of
ertugliflozin, an investigational oral SGLT-2 inhibitor in development
to help improve glycemic control in adults with type 2 diabetes, met
their primary endpoints. In the studies, both doses of ertugliflozin
tested (5 mg and 15 mg daily) achieved statistically significant
reductions in A1C, a measure of average blood glucose over a two- to
three-month timeframe, when added to metformin or in initial
co-administration with sitagliptin. The results of these studies,
along with 52-week extension data from three other studies in the
VERTIS clinical development program of ertugliflozin, were presented
at the 77th Scientific Sessions of the American Diabetes
Association.
-
PF-06439535 (proposed biosimilar bevacizumab) -- In July 2017,
Pfizer announced that the REFLECTIONS B7391003 study, a comparative,
confirmatory safety and efficacy study of PF-06439535 versus Avastin®(7)
(bevacizumab), met its primary endpoint, demonstrating equivalence of
objective response rate of PF-06439535 versus Avastin®(7),
both taken in combination with carboplatin/paclitaxel, for the first
line treatment of patients with advanced non-squamous non-small cell
lung cancer.
-
Talazoparib (MDV3800) -- In June 2017, Pfizer announced Phase 2
data showing that its investigational, dual-mechanism poly ADP ribose
polymerase (PARP) inhibitor, talazoparib, demonstrated anti-tumor
activity in patients with germline (inherited) BRCA1/2-positive
(gBRCA+) advanced breast cancer. Results from the Phase 2 ABRAZO trial
were presented during an oral session at the 53rd Annual
Meeting of the American Society of Clinical Oncology (ASCO). ABRAZO is
an open-label Phase 2, two-stage, single arm, parallel cohort study
that investigated the clinical efficacy and safety of single-agent
talazoparib in 83 evaluable, heavily pretreated gBRCA+ advanced breast
cancer patients. The primary endpoint was objective response rate
(ORR) by independent radiology review. Cohort 1 consisted of 49
patients who previously responded to platinum-based chemotherapy and
subsequently developed disease progression. A 21% ORR (95% CI: 10-35)
was observed in this group of patients. Cohort 2 consisted of 35
patients who developed disease progression following at least three
lines of non-platinum-based therapy. This group of patients had a 37%
ORR (95% CI: 22-55). Talazoparib is also being assessed in the
open-label Phase 3 randomized, parallel, two-arm EMBRACA trial.
EMBRACA is evaluating talazoparib vs. protocol-specific physician's
choice of chemotherapy in patients with advanced and/or metastatic
gBRCA+ breast cancer who have received zero to three prior
chemotherapy regimens for advanced disease. The EMBRACA trial has
completed enrollment and top-line results are expected by January 2018.
-
Tanezumab (PF-4383119) -- In June 2017, Pfizer and Eli Lilly
and Company (Lilly) announced that the FDA granted Fast Track
designation for tanezumab for the treatment of chronic pain in
patients with osteoarthritis and chronic low back pain. Tanezumab is
an investigational humanized monoclonal antibody that selectively
targets, binds to and inhibits nerve growth factor (NGF). It is the
first and only NGF inhibitor to receive Fast Track designation. In
2013, Pfizer and Lilly entered into a worldwide co-development and
co-commercialization agreement for the advancement of tanezumab.
Corporate Developments
-
In July 2017, Pfizer and Basilea Pharmaceutica Ltd. (Basilea)
completed a licensing agreement whereby Pfizer obtained the exclusive
commercialization rights in Europe to Cresemba (isavuconazole), a
novel anti-fungal treatment for adult patients with diagnosed invasive
aspergillosis and mucormycosis, two serious infections associated with
high morbidity and mortality among immunocompromised patients. Under
the terms of the agreement, Pfizer will have exclusive rights to
distribute and commercialize Cresemba in Europe, including Austria,
France, Germany, Italy and the United Kingdom, where it is currently
available. These rights do not extend to the Nordic countries
(Denmark, Finland, Norway, Sweden and Iceland). In addition, Pfizer
will be responsible for additional Cresemba launches, predominantly in
Europe, which are expected throughout 2017 and 2018. Basilea will
remain the marketing authorization holder for the EU.
-
In May 2017, Sangamo and Pfizer announced an exclusive, global
collaboration and license agreement for the development and
commercialization of gene therapy programs for Hemophilia A, including
SB-525, one of Sangamo's four lead product candidates. Under the terms
of the agreement, Pfizer recorded $75 million in research and
development expenses in the second quarter of 2017, which included an
upfront payment of $70 million to Sangamo. Sangamo will be responsible
for conducting the SB-525 Phase 1/2 clinical study and certain
manufacturing activities. Pfizer will be operationally and financially
responsible for subsequent research, development, manufacturing and
commercialization activities for SB-525 and additional products, if
any. Sangamo is eligible to receive potential milestone payments of up
to $475 million, including up to $300 million for the development and
commercialization of SB-525 and up to $175 million for additional
Hemophilia A gene therapy product candidates that may be developed
under the agreement. Sangamo will also receive tiered double-digit
royalties on net sales. Additionally, Sangamo will be collaborating
with Pfizer on manufacturing and technical operations utilizing viral
delivery vectors.
-
Pfizer announced in February 2017 that it had entered into an
accelerated share repurchase agreement with Citibank N.A. (Citibank)
to repurchase $5 billion of Pfizer's common stock. Pursuant to the
terms of the agreement, on February 6, 2017, Pfizer paid $5 billion to
Citibank and received an initial delivery of approximately 126 million
shares of Pfizer common stock from Citibank. Upon settlement of the
agreement in May 2017 and pursuant to the agreement's settlement
terms, Citibank delivered approximately 24 million additional shares
of Pfizer common stock to Pfizer. After giving effect to the
accelerated share repurchase agreement, Pfizer's remaining
share-purchase authorization was approximately $6.4 billion as of
August 1, 2017.
Please find Pfizer's press release and associated financial tables,
including reconciliations of certain GAAP reported to non-GAAP adjusted
information, at the following hyperlink:
https://s21.q4cdn.com/317678438/files/doc_financials/Quarterly/2017/Q2_2017_Earnings_Press_Release.pdf
(Note: If clicking on the above link does not open up a new web page,
you may need to cut and paste the above URL into your browser's address
bar.)
For additional details, see the associated financial schedules and
product revenue tables attached to the press release located at the
hyperlink referred to above and the attached disclosure notice.
(1)
|
|
Revenues is defined as revenues in accordance with U.S. generally
accepted accounting principles (GAAP). Reported net income is
defined as net income attributable to Pfizer Inc. in accordance
with U.S. GAAP. Reported diluted earnings per share (EPS) is
defined as reported diluted EPS attributable to Pfizer Inc. common
shareholders in accordance with U.S. GAAP.
|
|
|
|
(2)
|
|
Adjusted income and its components and Adjusted diluted EPS are
defined as reported U.S. GAAP net income(1) and its
components and reported diluted EPS(1) excluding
purchase accounting adjustments, acquisition-related costs,
discontinued operations and certain significant items (some of
which may recur, such as restructuring or legal charges, but which
management does not believe are reflective of ongoing core
operations). Adjusted cost of sales, Adjusted selling,
informational and administrative (SI&A) expenses, Adjusted
research and development (R&D) expenses and Adjusted other
(income)/deductions are income statement line items prepared on
the same basis as, and therefore components of, the overall
Adjusted income measure. As described in the "Management's
Discussion and Analysis of Financial Condition and Results of
Operations--Non-GAAP Financial Measure (Adjusted Income)" section
of Pfizer's Quarterly Report on Form 10-Q for the fiscal quarter
ended April 2, 2017, management uses Adjusted income, among other
factors, to set performance goals and to measure the performance
of the overall company. Because Adjusted income is an important
internal measurement for Pfizer, management believes that
investors' understanding of our performance is enhanced by
disclosing this performance measure. Pfizer reports Adjusted
income, certain components of Adjusted income, and Adjusted
diluted EPS in order to portray the results of the Company's major
operations--the discovery, development, manufacture, marketing and
sale of prescription medicines, vaccines and consumer healthcare
(OTC) products--prior to considering certain income statement
elements. See the accompanying reconciliations of certain GAAP
Reported to Non-GAAP Adjusted information for the second quarter
and first six months of 2017 and 2016. The Adjusted income and its
components and Adjusted diluted EPS measures are not, and should
not be viewed as, substitutes for U.S. GAAP net income and its
components and diluted EPS.
|
|
|
|
(3)
|
|
Pfizer's fiscal year-end for international subsidiaries is
November 30 while Pfizer's fiscal year-end for U.S. subsidiaries
is December 31. Therefore, Pfizer's second quarter and first six
months for U.S. subsidiaries reflect the three and six months
ending on July 2, 2017 and July 3, 2016 while Pfizer's second
quarter and first six months for subsidiaries operating outside
the U.S. reflect the three and six months ending on May 28, 2017
and May 29, 2016.
|
|
|
|
(4)
|
|
The following acquisitions and divestitures impacted financial
results for the periods presented:
|
-
On June 24, 2016, Pfizer acquired Anacor Pharmaceuticals, Inc.
(Anacor). Therefore, financial results for the second quarter and
first six months of 2017 reflect legacy Anacor operations.
-
On September 28, 2016, Pfizer acquired Medivation, Inc. (Medivation).
Therefore, financial results for the second quarter and first six
months of 2017 reflect legacy Medivation operations.
-
On December 22, 2016, Pfizer completed the acquisition of the
development and commercialization rights to AstraZeneca's small
molecule anti-infective business, primarily outside the U.S.
Therefore, financial results for the second quarter and first six
months of 2017 reflect contributions from certain legacy AstraZeneca
products.
-
On February 3, 2017, Pfizer completed the sale of its global infusion
therapy net assets, Hospira Infusion Systems (HIS). Therefore,
financial results for second-quarter 2017 do not reflect any
contribution from legacy HIS operations while the first six months of
2017 reflect approximately one month of legacy HIS domestic operations
and approximately two months of legacy HIS international operations.(3)
Financial results for the second quarter and first six months of 2016
reflect three and six months of legacy HIS global operations,
respectively.
(5)
|
|
References to operational variances in this press release pertain
to period-over-period growth rates that exclude the impact of
foreign exchange. The operational variances are determined by
multiplying or dividing, as appropriate, the current period U.S.
dollar results by the current period average foreign exchange
rates and then multiplying or dividing, as appropriate, those
amounts by the prior-year period average foreign exchange rates.
Although exchange rate changes are part of Pfizer's business, they
are not within Pfizer's control. Exchange rate changes, however,
can mask positive or negative trends in the business; therefore,
Pfizer believes presenting operational variances provides useful
information in evaluating the results of its business.
|
|
|
|
(6)
|
|
The 2017 financial guidance reflects the following:
|
-
Pfizer does not provide guidance for GAAP Reported financial measures
(other than Revenues) or a reconciliation of forward-looking non-GAAP
financial measures to the most directly comparable GAAP Reported
financial measures on a forward-looking basis because it is unable to
predict with reasonable certainty the ultimate outcome of pending
litigation, unusual gains and losses, acquisition-related expenses and
potential future asset impairments without unreasonable effort. These
items are uncertain, depend on various factors, and could have a
material impact on GAAP Reported results for the guidance period.
-
Does not assume the completion of any business development
transactions not completed as of July 2, 2017, including any one-time
upfront payments associated with such transactions.
-
Exchange rates assumed are a blend of the actual exchange rates in
effect through June 2017 and mid-July 2017 exchange rates for the
remainder of the year.
-
Reflects an anticipated negative revenue impact of $2.4 billion due to
recent and expected generic and biosimilar competition for certain
products that have recently lost or are anticipated to soon lose
patent protection.
-
Reflects the anticipated negative impact of $0.2 billion on revenues
and $0.01 on Adjusted diluted EPS(2) as a result of
unfavorable changes in foreign exchange rates relative to the U.S.
dollar compared to foreign exchange rates from 2016.
-
Guidance for Adjusted diluted EPS(2) assumes diluted
weighted-average shares outstanding of between 6.0 and 6.1 billion
shares, which reflects the impact of the $5 billion accelerated share
repurchase agreement executed in February 2017 and completed in May
2017.
(7)
|
|
Avastin® is a registered U.S. trademark of Genentech, Inc.
|
|
DISCLOSURE NOTICE: Except where otherwise noted, the information
contained in this earnings release and the related attachments is as of
August 1, 2017. We assume no obligation to update any forward-looking
statements contained in this earnings release and the related
attachments as a result of new information or future events or
developments.
This earnings release and the related attachments contain
forward-looking statements about our anticipated future operating and
financial performance, business plans and prospects, in-line products
and product candidates, including anticipated regulatory submissions,
approvals, performance and potential benefits of Pfizer's products and
product candidates, strategic reviews, capital allocation,
business-development plans, the benefits expected from our acquisitions
and other business development activities and plans relating to share
repurchases and dividends, among other things, that involve substantial
risks and uncertainties. You can identify these statements by the fact
that they use future dates or use words such as "will," "may," "could,"
"likely," "ongoing," "anticipate," "estimate," "expect," "project,"
"intend," "plan," "believe," "target," "forecast," "goal," "objective,"
"aim" and other words and terms of similar meaning. Among the factors
that could cause actual results to differ materially from past results
and future plans and projected future results are the following:
-
the outcome of research and development activities, including, without
limitation, the ability to meet anticipated pre-clinical and clinical
trial commencement and completion dates, regulatory submission and
approval dates, and launch dates for product candidates, as well as
the possibility of unfavorable pre-clinical and clinical trial
results, including unfavorable new clinical data and additional
analyses of existing clinical data;
-
decisions by regulatory authorities regarding whether and when to
approve our drug applications, which will depend on the assessment by
such regulatory authorities of the benefit-risk profile suggested by
the totality of the efficacy and safety information submitted;
decisions by regulatory authorities regarding labeling, ingredients
and other matters that could affect the availability or commercial
potential of our products; and uncertainties regarding our ability to
address the comments in complete response letters received by us with
respect to certain of our drug applications to the satisfaction of the
FDA;
-
the speed with which regulatory authorizations, pricing approvals and
product launches may be achieved;
-
the outcome of post-approval clinical trials, which could result in
the loss of marketing approval for a product or changes in the
labeling for, and/or increased or new concerns about the safety or
efficacy of, a product that could affect its availability or
commercial potential;
-
risks associated with interim data, including the risk that final
results of studies for which interim data have been provided and/or
additional clinical trials may be different from (including less
favorable than) the interim data results and may not support further
clinical development of the applicable product candidate or indication;
-
the success of external business-development activities, including the
ability to satisfy the conditions to closing of announced transactions
in the anticipated time frame or at all;
-
competitive developments, including the impact on our competitive
position of new product entrants, in-line branded products, generic
products, private label products, biosimilars and product candidates
that treat diseases and conditions similar to those treated by our
in-line drugs and drug candidates;
-
the implementation by the FDA and regulatory authorities in certain
other countries of an abbreviated legal pathway to approve biosimilar
products, which could subject our biologic products to competition
from biosimilar products, with attendant competitive pressures, after
the expiration of any applicable exclusivity period and patent rights;
-
risks related to our ability to develop and launch biosimilars,
including risks associated with "at risk" launches, defined as the
marketing of a product by Pfizer before the final resolution of
litigation (including any appeals) brought by a third party alleging
that such marketing would infringe one or more patents owned or
controlled by the third party;
-
the ability to meet competition from generic, branded and biosimilar
products after the loss or expiration of patent protection for our
products or competitor products;
-
the ability to successfully market both new and existing products
domestically and internationally;
-
difficulties or delays in manufacturing, including possible legal or
regulatory actions, such as warning letters, suspension of
manufacturing, seizure of product, injunctions or voluntary recall of
a product;
-
trade buying patterns;
-
the impact of existing and future legislation and regulatory
provisions on product exclusivity;
-
trends toward managed care and healthcare cost containment, and our
ability to obtain or maintain timely or adequate pricing or formulary
placement for our products;
-
the impact of any significant spending reductions or cost controls
affecting Medicare, Medicaid or other publicly funded or subsidized
health programs or changes in the tax treatment of employer-sponsored
health insurance that may be implemented, and/or any significant
additional taxes or fees that may be imposed on the pharmaceutical
industry as part of any broad deficit-reduction effort;
-
the impact of any U.S. healthcare reform or legislation, including any
repeal, substantial modification or invalidation of any or all of the
provisions of the U.S. Patient Protection and Affordable Care Act, as
amended by the Health Care and Education Reconciliation Act;
-
U.S. federal or state legislation or regulatory action and/or policy
efforts affecting, among other things, pharmaceutical product pricing,
reimbursement or access, including under Medicaid, Medicare and other
publicly funded or subsidized health programs; patient out-of-pocket
costs for medicines, manufacturer prices and/or price increases that
could result in new mandatory rebates and discounts or other pricing
restrictions; the importation of prescription drugs from outside the
U.S. at prices that are regulated by governments of various foreign
countries; restrictions on direct-to-consumer advertising; limitations
on interactions with healthcare professionals; or the use of
comparative effectiveness methodologies that could be implemented in a
manner that focuses primarily on the cost differences and minimizes
the therapeutic differences among pharmaceutical products and
restricts access to innovative medicines; as well as pricing pressures
for our products as a result of highly competitive insurance markets;
-
legislation or regulatory action in markets outside the U.S. affecting
pharmaceutical product pricing, reimbursement or access, including, in
particular, continued government-mandated reductions in prices and
access restrictions for certain biopharmaceutical products to control
costs in those markets;
-
the exposure of our operations outside the U.S. to possible capital
and exchange controls, expropriation and other restrictive government
actions, changes in intellectual property legal protections and
remedies, as well as political unrest, unstable governments and legal
systems and inter-governmental disputes;
-
contingencies related to actual or alleged environmental contamination;
-
claims and concerns that may arise regarding the safety or efficacy of
in-line products and product candidates;
-
any significant breakdown, infiltration or interruption of our
information technology systems and infrastructure;
-
legal defense costs, insurance expenses and settlement costs;
-
the risk of an adverse decision or settlement and the adequacy of
reserves related to legal proceedings, including patent litigation,
product liability and other product-related litigation, including
personal injury, consumer, off-label promotion, securities, antitrust
and breach of contract claims, commercial, environmental, government
investigations, employment and other legal proceedings, including
various means for resolving asbestos litigation, as well as tax issues;
-
our ability to protect our patents and other intellectual property,
both domestically and internationally;
-
interest rate and foreign currency exchange rate fluctuations,
including the impact of possible currency devaluations in countries
experiencing high inflation rates and the volatility following the
United Kingdom (U.K.) referendum in which voters approved the exit
from the EU;
-
governmental laws and regulations affecting domestic and foreign
operations, including, without limitation, tax obligations and changes
affecting the tax treatment by the U.S. of income earned outside the
U.S. that may result from pending and possible future proposals;
-
any significant issues involving our largest wholesale distributors,
which account for a substantial portion of our revenues;
-
the possible impact of the increased presence of counterfeit medicines
in the pharmaceutical supply chain on our revenues and on patient
confidence in the integrity of our medicines;
-
the end result of any negotiations between the U.K. government and the
EU regarding the terms of the U.K.'s exit from the EU, which could
have implications on our research, commercial and general business
operations in the U.K. and the EU;
-
any significant issues that may arise related to the outsourcing of
certain operational and staff functions to third parties, including
with regard to quality, timeliness and compliance with applicable
legal requirements and industry standards;
-
any significant issues that may arise related to our joint ventures
and other third-party business arrangements;
-
changes in U.S. generally accepted accounting principles;
-
changes in interpretations of existing laws and regulations, or
changes in laws and regulations, in the U.S. and other countries;
-
uncertainties related to general economic, political, business,
industry, regulatory and market conditions including, without
limitation, uncertainties related to the impact on us, our customers,
suppliers and lenders and counterparties to our foreign-exchange and
interest-rate agreements of challenging global economic conditions and
recent and possible future changes in global financial markets; and
the related risk that our allowance for doubtful accounts may not be
adequate;
-
any changes in business, political and economic conditions due to
actual or threatened terrorist activity in the U.S. and other parts of
the world, and related U.S. military action overseas;
-
growth in costs and expenses;
-
changes in our product, segment and geographic mix;
-
the impact of purchase accounting adjustments, acquisition-related
costs, discontinued operations and certain significant items;
-
the impact of acquisitions, divestitures, restructurings, internal
reorganizations, product recalls, withdrawals and other unusual items,
including our ability to realize the projected benefits of our
cost-reduction and productivity initiatives and of the internal
separation of our commercial operations into our current operating
structure;
-
the risk of an impairment charge related to our intangible assets,
goodwill or equity-method investments;
-
risks related to internal control over financial reporting; and
-
risks and uncertainties related to our acquisitions of Hospira, Inc.
(Hospira), Anacor Pharmaceuticals, Inc. (Anacor), Medivation, Inc.
(Medivation) and AstraZeneca's small molecule anti-infectives
business, including, among other things, the ability to realize the
anticipated benefits of those acquisitions, including the possibility
that expected cost savings related to the acquisition of Hospira and
accretion related to the acquisitions of Hospira, Anacor and
Medivation will not be realized or will not be realized within the
expected time frame; the risk that the businesses will not be
integrated successfully; disruption from the transactions making it
more difficult to maintain business and operational relationships;
significant transaction costs; risks related to our ability to grow
revenues for Xtandi and expand Xtandi into the non-metastatic
castration-resistant prostate cancer setting; and unknown liabilities.
We cannot guarantee that any forward-looking statement will be realized.
Achievement of anticipated results is subject to substantial risks,
uncertainties and inaccurate assumptions. Should known or unknown risks
or uncertainties materialize or should underlying assumptions prove
inaccurate, actual results could vary materially from past results and
those anticipated, estimated or projected. Investors should bear this in
mind as they consider forward-looking statements, and are cautioned not
to put undue reliance on forward-looking statements. A further list and
description of risks, uncertainties and other matters can be found in
our Annual Report on Form 10-K for the fiscal year ended December 31,
2016 and in our subsequent reports on Form 10-Q, in each case including
in the sections thereof captioned "Forward-Looking Information and
Factors That May Affect Future Results" and "Item 1A. Risk Factors", and
in our subsequent reports on Form 8-K.
The operating segment information provided in this earnings release and
the related attachments does not purport to represent the revenues,
costs and income from continuing operations before provision for taxes
on income that each of our operating segments would have recorded had
each segment operated as a standalone company during the periods
presented.
This earnings release may include discussion of certain clinical studies
relating to various in-line products and/or product candidates. These
studies typically are part of a larger body of clinical data relating to
such products or product candidates, and the discussion herein should be
considered in the context of the larger body of data. In addition,
clinical trial data are subject to differing interpretations, and, even
when we view data as sufficient to support the safety and/or
effectiveness of a product candidate or a new indication for an in-line
product, regulatory authorities may not share our views and may require
additional data or may deny approval altogether.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170801005486/en/
[ Back To TMCnet.com's Homepage ]
|